Overview

A Study to Evaluate the Efficacy and Safety of IV Peramivir in Addition to Standard of Care Compared to Standard of Care Alone in Adults and Adolescents Who Are Hospitalized Due to Influenza

Status:
Terminated

Trial end date:
2013-10-01

Target enrollment:

Participant gender:

Summary

A Phase 3, multicenter, randomized, double-blind, controlled study to evaluate the efficacy and safety of peramivir administered intravenously in addition to standard of care compared to standard of care alone in adults and adolescents who are hospitalized due to serious influenza.

Phase:

Phase 3

Details

Lead Sponsor:

BioCryst Pharmaceuticals

Collaborator:

Department of Health and Human Services

Treatments:

Peramivir